RecruitingNCT00315380

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis

Sponsor

University of Pennsylvania

Enrollment

700 participants

Start Date

Apr 1, 2006

Study Type

OBSERVATIONAL

Conditions

Eosinophilic Granulomatosis With Polyangiitis Churg-Strauss Syndrome

Summary

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

Eligibility

Plain Language Summary

Simplified for easier understanding

This long-term study follows people diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare inflammatory disease affecting the blood vessels. Researchers collect data over time to understand how the disease progresses and how patients respond to treatment. You may be eligible if: - You have a confirmed diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) - If you are a minor, your parent or guardian is willing to provide informed consent You may NOT be eligible if: - You are unable to give informed consent and do not have a guardian who can sign the consent form Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(13)

University of California San Diego

San Diego, California, United States

National Jewish Health

Denver, Colorado, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

University of Utah

Salt Lake City, Utah, United States

St. Joseph's Healthcare

Hamilton, Ontario, Canada

Mount Sinai Hospital

Toronto, Ontario, Canada

medius KLINIK KIRCHHEIM

Kirchheim unter Teck, Germany

AOU Meyer IRCCS

Florence, Italy

Imperial College Healthcare NHS Trust/ Imperial College London

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT00315380

Related Trials

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT0604622234 locations

VCRC Tissue Repository

NCT029670688 locations

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

NCT059790512 locations